A client who is seen in the vision clinic has been diagnosed with glaucoma. What medication would the nurse expect to be included on the lifelong treatment plan for this client?

Choice A rationale Mydriatics are agents used to dilate the pupils by stimulating the iris dilator muscle or paralyzing the sphincter muscle. These medications are strictly contraindicated in most glaucoma patients, particularly those with narrow-angle glaucoma. Dilation of the pupil can bunch up the iris tissue in the drainage angle, blocking the outflow of aqueous humor. This obstruction causes a rapid increase in intraocular pressure, which can lead to permanent optic nerve damage and blindness. Choice B rationale Antifungal medications are utilized to treat ocular infections caused by various fungi, such as keratitis or endophthalmitis. Glaucoma is a chronic, non-infectious neurodegenerative condition characterized by elevated intraocular pressure rather than a microbial invasion. Therefore, antifungals do not address the underlying pathophysiology of aqueous humor production or drainage. Their use in a glaucoma treatment plan would be inappropriate unless a secondary fungal infection was specifically diagnosed by the provider. Choice C rationale Beta blockers are frequently used to treat glaucoma by reducing the production of aqueous humor by the ciliary body. While they are common, the question asks for a medication that is traditionally a cornerstone of lifelong management alongside others. Beta blockers work by blocking beta-adrenergic receptors in the eye. However, they carry systemic risks, such as bradycardia and bronchospasm, which may limit their use in patients with certain cardiac or respiratory conditions compared to other options. Choice D rationale Miotics, such as pilocarpine, are essential for lifelong glaucoma management because they cause pupillary constriction. By contracting the ciliary muscle, these agents increase the outflow of aqueous humor through the trabecular meshwork. This physical opening of the drainage pathways is vital for maintaining intraocular pressure within the safe range of 10 to 21 mmHg. Consistent use of miotics helps prevent the progressive optic nerve atrophy that defines the disease and leads to vision loss.